The 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline for high blood pressure (BP) management lowered thresholds for diagnosing and treating hypertension to 130/80 mm Hg for all adults.1 These recommendations were based primarily on the results of the Systolic Blood Pressure Intervention Trial (SPRINT) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial,1-3 which recruited patients at increased cardiovascular risk and imposed exclusion criteria related to comorbidities, life expectancy, and likelihood of medication adherence.2,3 In the present study, we used National Health and Nutrition Examination Survey (NHANES) data to evaluate whether patients enrolled in the SPRINT and ACCORD trials are representative of the US adult population who met criteria for additional pharmacotherapy by the ACC/AHA guideline.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Anderson TS, Odden M, Penko J, Kazi DS, Bellows BK, Bibbins-Domingo K. Generalizability of Clinical Trials Supporting the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. JAMA Intern Med. Published online March 16, 2020. doi:10.1001/jamainternmed.2020.0051
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: